Automatic Cell Processor for GMP Manufacture

A new automated cell processor will allow Oxford researchers to manufacture advanced cellular therapies for first-in-human clinical trials under strict regulatory standards. The University of Oxford currently lacks onsite Good Manufacturing Practice (GMP) capacity for producing cell-based treatments such as engineered T cells, gene-edited therapies, and expanded stem cells. Without this equipment, promising academic discoveries cannot be tested in patients because they cannot be manufactured to the safety and quality standards required for human trials. The CliniMACs Prodigy system fills that gap by automating the complex, sterile production of living cell therapies. If successful, the processor will enable early-phase clinical trials that de-risk new cellular technologies, increase the value of intellectual property, and strengthen links between academic research and the UK biopharmaceutical industry. The equipment is part of a wider £3 million university investment in dedicated clean room space at the Oxford Clinical Biomanufacturing Facility. The MRC is asked to part-fund the purchase, with Oxford providing 30% matching support. The immediate impact is on research infrastructure rather than on patients directly, but the ability to manufacture therapies for first-in-human trials is a necessary step before any new cell-based treatment can reach the clinic.